METHODS: The research was a multicenter retrospective observational study to examine the correlation between TFR and neutrophil counts before TKI discontinuation. The investigation included patients having Philadelphia chromosome-positive CML-CP who attempted the discontinuation of TKIs after a durable deep molecular response between January 2012 and July 2021 at four institutions in Japan.
RESULTS: 118 CML-CP patients in total discontinued TKIs and an estimated 36-month TFR rate was 65.1%. 52 patients received second-generation TKIs as frontline. Higher neutrophil count (>3210/μL) at TKIs discontinuation was determined as an independent prognostic variable for TFR in patients who received second-generation TKIs as frontline [(HR, 0.235 (95%, confidence interval (CI) 0.078-0.711); p = 0.010].
CONCLUSIONS: The neutrophil-mediated immunomodulation can be a significant component for the effective achievement of TFR in CML supported by our clinical observation.
方法:本研究是一项多中心回顾性观察研究,目的是检查TKI停药前TFR与中性粒细胞计数之间的相关性。调查包括费城染色体阳性CML-CP的患者,他们在2012年1月至2021年7月期间在日本的四家机构进行了持久的深层分子反应后,试图停用TKIs。
结果:118例CML-CP患者中,TKIs停止,估计36个月的TFR率为65.1%。52例患者接受了第二代TKIs作为前线治疗。在接受第二代TKIs作为前线[(HR,0.235(95%,置信区间(CI)0.078-0.711);p=0.010]。
结论:我们的临床观察支持,中性粒细胞介导的免疫调节可能是CML中有效实现TFR的重要组成部分。